Log in

NASDAQ:NK - Nantkwest Stock Price, Forecast & News

$4.89
-0.51 (-9.44 %)
(As of 02/26/2020 02:46 AM ET)
Today's Range
$4.70
Now: $4.89
$5.48
50-Day Range
$3.48
MA: $6.04
$7.38
52-Week Range
$0.95
Now: $4.89
$9.90
Volume1.04 million shs
Average Volume2.78 million shs
Market Capitalization$481.01 million
P/E RatioN/A
Dividend YieldN/A
Beta2.76
NantKwest, Inc, a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and NANT cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone858-633-0300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$50,000.00
Book Value$1.84 per share

Profitability

Net Income$-96,230,000.00
Net Margins-164,604.89%

Miscellaneous

Employees161
Market Cap$481.01 million
Next Earnings Date3/11/2020 (Estimated)
OptionableOptionable

Receive NK News and Ratings via Email

Sign-up to receive the latest news and ratings for NK and its competitors with MarketBeat's FREE daily newsletter.


Nantkwest (NASDAQ:NK) Frequently Asked Questions

What is Nantkwest's stock symbol?

Nantkwest trades on the NASDAQ under the ticker symbol "NK."

How were Nantkwest's earnings last quarter?

Nantkwest Inc (NASDAQ:NK) released its quarterly earnings results on Tuesday, November, 5th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.18) by $0.02. The biotechnology company had revenue of $0.01 million for the quarter. Nantkwest had a negative net margin of 164,604.89% and a negative return on equity of 44.91%. View Nantkwest's Earnings History.

When is Nantkwest's next earnings date?

Nantkwest is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for Nantkwest.

What price target have analysts set for NK?

1 analysts have issued 1-year price objectives for Nantkwest's shares. Their forecasts range from $1.00 to $1.00. On average, they anticipate Nantkwest's share price to reach $1.00 in the next twelve months. This suggests that the stock has a possible downside of 79.6%. View Analyst Price Targets for Nantkwest.

What is the consensus analysts' recommendation for Nantkwest?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nantkwest in the last year. There are currently 1 sell rating for the stock, resulting in a consensus recommendation of "Sell." View Analyst Ratings for Nantkwest.

Has Nantkwest been receiving favorable news coverage?

News headlines about NK stock have been trending neutral this week, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Nantkwest earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Nantkwest.

Are investors shorting Nantkwest?

Nantkwest saw a increase in short interest in January. As of January 15th, there was short interest totalling 2,830,000 shares, an increase of 34.1% from the December 31st total of 2,110,000 shares. Based on an average daily volume of 803,300 shares, the days-to-cover ratio is currently 3.5 days. Approximately 31.0% of the shares of the stock are sold short. View Nantkwest's Current Options Chain.

Who are some of Nantkwest's key competitors?

What other stocks do shareholders of Nantkwest own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nantkwest investors own include Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Amicus Therapeutics (FOLD), Novavax (NVAX), Mallinckrodt (MNK), Fate Therapeutics (FATE), Immunomedics (IMMU), Opko Health (OPK), Selecta Biosciences (SELB) and Vodafone Group (VOD).

Who are Nantkwest's key executives?

Nantkwest's management team includes the folowing people:
  • Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.D., FACS, Exec. Chairman & CEO (Age 66)
  • Dr. Barry J. Simon, Pres, Chief Admin. Officer & Exec. Director (Age 54)
  • Mr. Richard J. Tajak, Consultant (Age 66)
  • Ms. Sonja Nelson, CFO & Principal Financial Officer (Age 46)
  • Mr. David J. Pyrce, Chief Commercial Officer and Sr. VP of Innovation & Investor Relations (Age 62)

When did Nantkwest IPO?

(NK) raised $150 million in an initial public offering (IPO) on Tuesday, July 28th 2015. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. BofA Merrill Lynch, Citigroup, Jefferies and Piper Jaffray acted as the underwriters for the IPO and MLV & Co. was co-manager.

Who are Nantkwest's major shareholders?

Nantkwest's stock is owned by many different of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (1.66%), Geode Capital Management LLC (0.29%), Charles Schwab Investment Management Inc. (0.17%), Credit Suisse AG (0.13%), Laurion Capital Management LP (0.02%) and Oppenheimer & Co. Inc. (0.02%). Company insiders that own Nantkwest stock include John C Thomas and Steve Gorlin. View Institutional Ownership Trends for Nantkwest.

Which institutional investors are selling Nantkwest stock?

NK stock was sold by a variety of institutional investors in the last quarter, including Oppenheimer & Co. Inc., State Street Corp, UBS Group AG, Victory Capital Management Inc. and Victory Capital Management Inc.. View Insider Buying and Selling for Nantkwest.

Which institutional investors are buying Nantkwest stock?

NK stock was purchased by a variety of institutional investors in the last quarter, including Credit Suisse AG, Renaissance Technologies LLC, Charles Schwab Investment Management Inc., Geode Capital Management LLC, Laurion Capital Management LP, Alpine Global Management LLC and National Asset Management Inc.. View Insider Buying and Selling for Nantkwest.

How do I buy shares of Nantkwest?

Shares of NK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Nantkwest's stock price today?

One share of NK stock can currently be purchased for approximately $4.89.

How big of a company is Nantkwest?

Nantkwest has a market capitalization of $481.01 million and generates $50,000.00 in revenue each year. The biotechnology company earns $-96,230,000.00 in net income (profit) each year or ($1.22) on an earnings per share basis. Nantkwest employs 161 workers across the globe.View Additional Information About Nantkwest.

What is Nantkwest's official website?

The official website for Nantkwest is http://www.nantkwest.com/.

How can I contact Nantkwest?

Nantkwest's mailing address is 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-633-0300 or via email at [email protected]


MarketBeat Community Rating for Nantkwest (NASDAQ NK)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  257 (Vote Outperform)
Underperform Votes:  240 (Vote Underperform)
Total Votes:  497
MarketBeat's community ratings are surveys of what our community members think about Nantkwest and other stocks. Vote "Outperform" if you believe NK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel